Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.60 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 6/20 | 0.38 |
| ▸ | BRAF | P15056 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878162 | 0.90 | LRRK2 (0.47) | LRRK2SMG1MTOR | |
| SCHEMBL10224711 | 0.84 | LRRK2 (0.60) | LRRK2 | |
| SCHEMBL13834275 | 0.83 | LRRK2 (0.47) | LRRK2SMG1MTOR | |
| SCHEMBL13834183 | 0.80 | LRRK2 (0.60) | LRRK2 | |
| SCHEMBL2630810 | 0.79 | LRRK2 (0.49) | LRRK2SMG1MTOR | |
| SCHEMBL875506 | 0.79 | LRRK2 (0.54) | LRRK2 | |
| SCHEMBL10225770 | 0.79 | LRRK2 (0.63) | LRRK2 | |
| SCHEMBL875707 | 0.75 | LRRK2 (1.00) | LRRK2 | |
| SCHEMBL16025749 | 0.75 | LRRK2 (0.47) | LRRK2SMG1MTORABL1RAF1 | |
| SCHEMBL16025720 | 0.75 | LRRK2 (0.48) | LRRK2SMG1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569281-B2 | Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-29 | — | — | US | disclosed |
| CN-103261196-A | Pyrazolopyridines as inhibitors of the kinase lrrk2 | MEDICAL RES COUNCIL TECHNOLOGY | 2013-08-21 | — | — | CN | disclosed |
| EP-2619201-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | Medical Research Council Technology (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | LRRK2 1512/4885SMG1 2840/4885MTOR 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.